In a significant blow to one of the most highly anticipated assets in modern oncology, the U.S. Food and Drug Administration (FDA) has officially rejected the Biologics License Application (BLA) for ivonescimab, a bispecific antibody developed by Akeso and licensed to Miami-based Summit Therapeutics. The decision, announced by the company on Sunday, centers on a critical regulatory disagreement: the FDA’s insistence that a cancer therapy must demonstrate a clear survival benefit at the time of primary trial analysis to earn approval.
The rejection has sent shockwaves through the biotech sector, leading to a sharp decline in market valuation for both Summit and its Chinese partner, Akeso. As the dust settles, industry analysts and investors are left grappling with the broader implications of this decision for the future of "dual-action" immunotherapies and the standard of evidence required for drugs moving from international trial sites to the U.S. market.
The Core Dispute: Efficacy vs. Progression-Free Survival
At the heart of the regulatory impasse is the "HARMONi" clinical trial. Summit Therapeutics sought approval for a combination regimen of ivonescimab and chemotherapy specifically for patients with EGFR-mutated, non-small cell lung cancer (NSCLC) who had already progressed on targeted therapies.
The clinical data from the HARMONi study presented a nuanced picture. While the combination of ivonescimab and chemotherapy successfully slowed disease progression—meaning patients lived longer without their tumors worsening—by more than two months compared to chemotherapy alone, it failed to show a statistically significant improvement in Overall Survival (OS) at the primary analysis.
For the FDA, the ability to delay tumor growth, known as Progression-Free Survival (PFS), was insufficient on its own to "support a positive benefit-risk profile." The agency has historically maintained a high bar for drugs in this setting, particularly when existing treatments are available. Summit attempted to bolster its case with an "after-the-fact" evaluation—a post-hoc analysis that included additional participants from non-Asian trial sites—which did suggest an improvement in survival. However, federal regulators were unmoved, dismissing the supplemental findings as insufficient to override the lack of primary evidence.
A Chronology of the Ivonescimab Narrative
The trajectory of ivonescimab has been marked by rapid ascent and subsequent intense scrutiny. Understanding the current setback requires a look at the drug’s recent history:
- 2022: Summit Therapeutics enters a landmark licensing agreement with Akeso, securing the rights to develop and commercialize ivonescimab, a bispecific antibody targeting both PD-1 and VEGF, outside of China.
- 2024: The drug captures the attention of the global oncology community after trial results demonstrate it can outperform Merck & Co.’s industry-standard immunotherapy, Keytruda, in certain lung cancer settings. This success triggers a surge in investor interest in bispecific drugs that target two proteins driving tumor growth simultaneously.
- 2025–2026: Following its early success, ivonescimab faces rigorous scrutiny. As data from various HARMONi-series trials emerge, critics begin to question whether the overwhelmingly positive results seen in China-based studies translate to global populations.
- Friday, Pre-Decision: As the FDA’s PDUFA (Prescription Drug User Fee Act) deadline approaches, market anxiety mounts. Summit shares slide by 6% in anticipation of the verdict.
- Monday, Post-Decision: Following the weekend announcement of the rejection, Summit Therapeutics shares plummet by 15%, while Akeso sees a 22% drop in its Hong Kong-traded shares.
Examining the Data: The "Higher Bar" Argument
Summit Therapeutics has publicly characterized the FDA’s decision as an outlier, arguing that the company is being held to a standard that has not been applied to other approved treatments for EGFR-mutated lung cancer.
"We are disappointed for patients and their families awaiting additional treatment options in this setting," said Robert Duggan, chairman and co-CEO of Summit. "We chose to pursue an ivonescimab regimen here based on the opportunity to provide another treatment option to help patients in need. In doing so, we believe the global HARMONi study provided the basis for a treatment option that these patients needed."
The company’s defense rests on the assertion that no other FDA-approved regimens in this specific therapeutic space have demonstrated a definitive survival benefit. By rejecting ivonescimab, critics of the decision argue that the FDA may be shifting the goalposts for novel drugs, potentially delaying the introduction of therapies that could provide meaningful clinical alternatives to existing standard-of-care options.
However, the scientific community remains divided. While some analysts, such as Tyler Van Buren of TD Cowen, had previously argued that the observed survival benefit in the expanded dataset should have been sufficient for approval, others were more cautious. Daina Graybosch of Leerink Partners had long warned that the FDA’s specific guidance mandated that survival benefits must be evident at the primary analysis stage.
Implications for Future Oncology Research
The rejection of ivonescimab serves as a cautionary tale for biotech companies relying on international clinical data to gain a foothold in the U.S. market. A recurring theme in recent years has been the "China-only" data hurdle; regulators have become increasingly wary of trials conducted solely in Asia, citing potential differences in patient populations, genetic backgrounds, and standard-of-care practices that may inflate the perceived efficacy of a drug.
The "Read-Through" Concern
The central question now facing investors is whether this rejection serves as a bellwether for the rest of the ivonescimab pipeline. Specifically, the industry is looking toward the upcoming results of a major study comparing the ivonescimab-chemo combination against the current "gold standard"—a combination of Keytruda and chemotherapy in first-line lung cancer.
Analysts are optimistic that this rejection will not derail the drug’s potential in larger, first-line settings. TD Cowen’s Van Buren noted that the current decision "should have limited read-through to the larger opportunity." The stakes for this next trial are significantly higher; if ivonescimab can prove its superiority over Keytruda in a primary, first-line setting, the recent regulatory hurdle in the EGFR-mutated secondary setting may eventually be viewed as a temporary delay rather than a structural failure.
The Standard of Evidence
This case underscores a growing tension in drug development: the demand for speed versus the requirement for statistical certainty. As the FDA faces pressure to bring innovative treatments to market, it must balance that urgency with the need to ensure that new drugs offer a clear, survival-extending benefit over current options. For Summit, the path forward will likely require a renewed dialogue with the FDA regarding trial design and perhaps a more robust demonstration of survival in subsequent, larger-scale trials.
The Road Ahead for Summit and Akeso
As Summit Therapeutics pivots, the focus will undoubtedly shift to the "HARMONi-6" trial and other ongoing studies. The company is at a crossroads where it must prove that its drug is not just a scientific success in the laboratory, but a robust clinical tool that can satisfy the most stringent regulatory requirements in the world.
For investors, the volatility surrounding the stock is a reminder of the inherent risks in biotech. Ivonescimab remains a "closely watched" drug for a reason—the dual-target mechanism remains one of the most promising avenues in oncology. However, as the FDA has demonstrated, the path to approval is rarely linear. Whether Summit can reconcile its clinical data with the FDA’s expectations will determine not only the future of ivonescimab but potentially the viability of the entire bispecific immunotherapy class in the U.S. market.
In the coming months, the results from the first-line lung cancer trials will be the definitive test. If those results mirror the success seen in previous studies, the current rejection may be viewed as a minor bump in the road. If not, the questions regarding the efficacy of ivonescimab will only intensify, forcing the company to re-evaluate its strategy for global expansion. For now, the medical community waits, hoping that the promise of this innovative therapy can eventually overcome the regulatory barriers currently in its way.
